MedWatch

Sunstone: Here is the biotech investment for the future

The biotech companies of the future should be streamlined and to a much larger extent target exit opportunities in Asia, believes Peter Benson of Sunstone Capital. The venture capital fund is ready with freshly-printed venture capital for the sector.

Foto: Sunstone Capital / PR

The venture capital fund Sunstone Capital is ready with new ‘risk-willing’ capital for the money-starved biotech companies. The companies should shape themselves according to the demands of investors, and consequently company-structures will look very different in the future, assesses Peter Benson – leading partner in the fund.

“I think that we are going to see differently shaped companies in the future. These will be companies that are more focused, have less administrative top structure, have more active boards and are more industry-oriented. That‘s the tendency that we see,” he says.

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier